Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 5, 2008, Pages 909-913

  Llibre, J M ^a   Santos, J R ^a   Puig, T ^b   Molto J ^a   Ruiz, L ^b   Paredes, R ^a,b   Clotet, B ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b IrsiCaixa Foundation   (Spain)

Author keywords

Non nucleoside reverse transcriptase inhibitors; Resistance associated mutations; TMC125

Indexed keywords

EFAVIRENZ; ETRAVIRINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; MUTATIONAL ANALYSIS; NONHUMAN; VIRUS RESISTANCE;

ANTI-HIV AGENTS; BENZOXAZINES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MUTATION, MISSENSE; NEVIRAPINE; PYRIDAZINES;

EID: 54549118264     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn297     Document Type: Article

References (11)

1. Wensing AM, van der Vijver DA, Angarano G et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192 958-66.
2. Richman DD, Morton SC, Wrin T et al. The prevalence of antiretroviral drug resistance in the United States. Acquir Immune Defic Syndr 2004; 18: 1393-401.
3. Lazzarin A, Campbell T, Clotet B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 39-48.
4. Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 29-38.
5. Vingerhoets J, Buelens A, Peeters M et al. Impact of baseline NNRTI mutations on the virological response to TMC125 in the Phase III clinical DUET-1 and DUET-2. Presented at: The Sixteenth International HIV Drug Resistance Workshop, Barbados, 2007. Poster 32.
6. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007; 15: 119-25.
7. Andries K, Azijn H, Thielemans T et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48: 4680-6.
8. Vingerhoets J, Azijn H, Fransen E et al. TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J Virol 2005; 79: 12773-82.
9. Tambuyzer L, Vingerhoets J, Azijn H et al. Development of a list of mutations associated with NNRTI resistance for use in clinical research. Presented at: The Fifth European Drug Resistance Workshop, Cascais, Portugal, 2007. Poster 67.
10. TMC125-C223 Writing Group. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: Primary 24-week analysis. Acquir Immune Defic Syndr 2007; 21: F1-10.
11. Cohen C, Steinhart CR, Ward D et al. Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223. In: Abstracts of the Sixteenth International AIDS Conference, Toronto, Canada, 2006. Abstract TUPE0061, p. 306.